Xygrel 90 Tablet

Introduction

Xygrel is a prescription medication that contains the active ingredient Ticagrelor. It is available under the brand name Xygrel.

Uses

Xygrel is primarily used to prevent blood clots in patients with acute coronary syndrome (ACS). It is prescribed to reduce the risk of heart attack or stroke in individuals who have had a heart attack or unstable angina.

Dosage and Administration

Xygrel is typically taken orally with or without food. The recommended dosage may vary depending on the individual’s medical condition and response to treatment. Follow the dosage instructions provided by your healthcare professional. It is usually taken twice daily, approximately 12 hours apart.

Mechanism of Action

Ticagrelor, the active ingredient in Xygrel, belongs to a class of medications called platelet inhibitors. It works by preventing platelets in the blood from sticking together and forming clots. This helps to improve blood flow and reduce the risk of heart attack or stroke in patients with ACS.

Side Effects

Common side effects may include bleeding, shortness of breath, headache, and dizziness. Note that not all individuals will experience these side effects.

In rare cases, serious side effects may occur, such as severe bleeding, allergic reactions, or liver problems. If you experience any severe or persistent side effects, seek medical attention immediately.

Drug Interactions

Xygrel may interact with other medications, including certain blood thinners, antifungal medications, and certain antidepressants. Inform your healthcare professional about all the medications you are currently taking, including prescription, over-the-counter, and herbal products, to avoid potential drug interactions.

Precautions

Before taking Xygrel, inform your healthcare professional about any allergies, medical conditions, or medications you are currently taking. This medication may not be suitable for individuals with a history of bleeding disorders or those who are at an increased risk of bleeding.

Xygrel should be used with caution in patients with liver or kidney problems. Follow your healthcare professional’s instructions and undergo regular monitoring while taking this medication.

Storage

Xygrel should be stored at room temperature, away from moisture and heat. Keep the medication out of reach of children and pets. Do not use the medication if it has expired or if the packaging is damaged.

Patient Tips

• Take Xygrel as prescribed by your healthcare professional.
• Do not stop taking the medication without consulting your healthcare professional, as this may increase the risk of blood clots.
• If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule.
• Do not double dose to make up for a missed dose.
• Inform your healthcare professional about any unusual bleeding or bruising that occurs while taking Xygrel.
• attend regular check-ups with your healthcare professional to monitor your progress and assess the effectiveness of the medication.
• Follow a healthy lifestyle, including a balanced diet and regular exercise, to support your overall cardiovascular health.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Ticagrelor: an antiplatelet medicine to prevent blood clots (NHS UK) [Accessed 13 Jun. 2024] (online) Available at:
• Brilique 60 mg film coated tablets (Health Professionals SmPC) Available at:
• Ticagrelor (Drugs.com) [Accessed 0 Jun. 2024] (online) Available at:
• aspirin,buffered (calcium carbonate-magnesium) 325 mg tablet vorapaxar-ticagrelor no aspirin less than or equal to 100 (OTC) [Accessed 10 Jun. 2024] (online) Available at:
• Ticagrelor (MedlinePlus) [Accessed 22 Jun. 2024] (online) Available at:
• Kabil MF, Abo Dena AS, El-Sherbiny IM. Ticagrelor. Profiles Drug Subst Excip Relat Methodol. 2022;47:91-111. doi: 10.1016/bs.podrm.2021.10.003. Epub 2021 Dec 7. [Accessed 1 Jun. 2024] Available at: